JP2020519669A - ホモタウリンおよびその塩の製剤 - Google Patents

ホモタウリンおよびその塩の製剤 Download PDF

Info

Publication number
JP2020519669A
JP2020519669A JP2019563191A JP2019563191A JP2020519669A JP 2020519669 A JP2020519669 A JP 2020519669A JP 2019563191 A JP2019563191 A JP 2019563191A JP 2019563191 A JP2019563191 A JP 2019563191A JP 2020519669 A JP2020519669 A JP 2020519669A
Authority
JP
Japan
Prior art keywords
pellet
hpmc
less
release
ethyl cellulose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019563191A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020519669A5 (enExample
Inventor
ジョーンズ，スティーブン
ペイエ，ケネス
ドニパーシ，バドリーナート
Original Assignee
コンフルーエンス ファーマシューティカルズ，エルエルシー
コンフルーエンス ファーマシューティカルズ，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コンフルーエンス ファーマシューティカルズ，エルエルシー, コンフルーエンス ファーマシューティカルズ，エルエルシー filed Critical コンフルーエンス ファーマシューティカルズ，エルエルシー
Publication of JP2020519669A publication Critical patent/JP2020519669A/ja
Publication of JP2020519669A5 publication Critical patent/JP2020519669A5/ja
Priority to JP2023073242A priority Critical patent/JP7499539B2/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019563191A 2017-05-17 2018-05-17 ホモタウリンおよびその塩の製剤 Pending JP2020519669A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023073242A JP7499539B2 (ja) 2017-05-17 2023-04-27 ホモタウリンおよびその塩の製剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762507532P 2017-05-17 2017-05-17
US62/507,532 2017-05-17
US201862660690P 2018-04-20 2018-04-20
US62/660,690 2018-04-20
PCT/US2018/033205 WO2018213589A1 (en) 2017-05-17 2018-05-17 Formulations of homotaurines and salts thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023073242A Division JP7499539B2 (ja) 2017-05-17 2023-04-27 ホモタウリンおよびその塩の製剤

Publications (2)

Publication Number Publication Date
JP2020519669A true JP2020519669A (ja) 2020-07-02
JP2020519669A5 JP2020519669A5 (enExample) 2021-07-26

Family

ID=64274653

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019563191A Pending JP2020519669A (ja) 2017-05-17 2018-05-17 ホモタウリンおよびその塩の製剤
JP2023073242A Active JP7499539B2 (ja) 2017-05-17 2023-04-27 ホモタウリンおよびその塩の製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023073242A Active JP7499539B2 (ja) 2017-05-17 2023-04-27 ホモタウリンおよびその塩の製剤

Country Status (8)

Country Link
US (1) US12042566B2 (enExample)
EP (1) EP3624788A4 (enExample)
JP (2) JP2020519669A (enExample)
KR (1) KR20200005576A (enExample)
AU (2) AU2018269557B2 (enExample)
IL (1) IL270654B2 (enExample)
WO (1) WO2018213589A1 (enExample)
ZA (1) ZA201908264B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL270654B2 (en) 2017-05-17 2024-07-01 Confluence Pharmaceuticals Llc Formulations of homotaurines and salts thereof
WO2025163673A1 (en) * 2024-01-29 2025-08-07 Micro Labs Limited Dose-dumping resistant tablets of acamprosate calcium

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04224517A (ja) * 1990-04-17 1992-08-13 Giuliani Spa 標的制御釈放薬剤
JP2001199878A (ja) * 1999-09-13 2001-07-24 Lab Del Dr Esteve Sa 酸に不安定ベンズイミダゾールを含有する修飾された放出特性の経口用固形製剤
JP2012254993A (ja) * 2004-05-11 2012-12-27 Bayer Pharma AG バルデナフィルを含有する制御放出製剤
JP2014508812A (ja) * 2011-03-23 2014-04-10 アイアンショア ファーマシューティカルズ アンド ディベロップメント， インコーポレイテッド 注意欠陥障害の処置のための方法および組成物
JP2015131864A (ja) * 1998-10-01 2015-07-23 エラン ファーマ インターナショナル，リミティド 徐放性ナノ粒子組成物
JP2015528504A (ja) * 2012-09-12 2015-09-28 モノソル アールエックス リミテッド ライアビリティ カンパニー 抗疼痛及び抗嘔気及び／又は抗嘔吐組み合わせ組成物
WO2016179252A1 (en) * 2015-05-04 2016-11-10 Confluence Pharmaceuticals, Llc Sprinkle formulations of acamprosate

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01280192A (ja) 1988-10-25 1989-11-10 Nichibei Co Ltd ブラインド内装サッシ
PE57198A1 (es) 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
US6514530B2 (en) * 1997-09-09 2003-02-04 Alza Corporation Dosage form comprising means for changing drug delivery shape
FR2775188B1 (fr) 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
DE69936848T2 (de) 1998-04-14 2008-05-15 The General Hospital Corp., Boston Verwendung von d-serin oder d-alanin zur behandlung von schizophrenie
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
RU2375048C2 (ru) 2003-07-17 2009-12-10 Д-Р Редди'С Лабораторис Инк. Фармацевтическая композиция с набухающим покрытием
CA2504471A1 (en) * 2004-06-18 2005-12-18 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
DE102007009243A1 (de) 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets
JP2010532331A (ja) 2007-07-05 2010-10-07 アンセルム（アンスチチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル） 抗痙攣医薬組成物
ES2530047T3 (es) 2009-02-12 2015-02-26 Indiana University Research And Technology Corporation Material y métodos para el tratamiento de trastornos del desarrollo que incluyen autismo idiopático y comórbido
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US9195775B2 (en) 2009-06-26 2015-11-24 Iii Holdings 2, Llc System and method for managing and/or rendering internet multimedia content in a network
US20110142889A1 (en) 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
CA2850468C (en) * 2010-09-28 2019-08-13 Depomed, Inc. Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
TR201809351T4 (tr) * 2011-03-01 2018-07-23 Pharnext Nörolojik bozuklukların baklofen ve akamprosat tabanlı terapisi.
EP2727473A4 (en) 2011-06-28 2015-05-06 Vivozon Inc COMBINATION OF EFFICIENT SUBSTANCES WITH SYNERGISTIC EFFECTS OF MULTIPLE TARGETING AND USE THEREOF
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US9770423B2 (en) 2012-07-22 2017-09-26 Indiana University Research And Technology Corporation Modulation sAPP, sAAPα and BDNF levels in individuals diagnosed with FXS and ASD
CN105431144A (zh) 2013-06-05 2016-03-23 思康脑侒股份有限公司 阿坎酸制剂、使用阿坎酸制剂的方法以及包含阿坎酸制剂的组合
US10905672B2 (en) 2014-02-11 2021-02-02 Pharnext Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
HK1255584A1 (zh) 2015-08-04 2019-08-23 Confluence Pharmaceuticals, Llc 使用阿坎酸及d-环丝胺酸的联合疗法
JP6066009B1 (ja) 2016-06-16 2017-01-25 富士電機株式会社 ガス絶縁開閉装置用操作器及びそれを用いたガス絶縁開閉装置
IL270654B2 (en) 2017-05-17 2024-07-01 Confluence Pharmaceuticals Llc Formulations of homotaurines and salts thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04224517A (ja) * 1990-04-17 1992-08-13 Giuliani Spa 標的制御釈放薬剤
JP2015131864A (ja) * 1998-10-01 2015-07-23 エラン ファーマ インターナショナル，リミティド 徐放性ナノ粒子組成物
JP2001199878A (ja) * 1999-09-13 2001-07-24 Lab Del Dr Esteve Sa 酸に不安定ベンズイミダゾールを含有する修飾された放出特性の経口用固形製剤
JP2012254993A (ja) * 2004-05-11 2012-12-27 Bayer Pharma AG バルデナフィルを含有する制御放出製剤
JP2014508812A (ja) * 2011-03-23 2014-04-10 アイアンショア ファーマシューティカルズ アンド ディベロップメント， インコーポレイテッド 注意欠陥障害の処置のための方法および組成物
JP2015528504A (ja) * 2012-09-12 2015-09-28 モノソル アールエックス リミテッド ライアビリティ カンパニー 抗疼痛及び抗嘔気及び／又は抗嘔吐組み合わせ組成物
WO2016179252A1 (en) * 2015-05-04 2016-11-10 Confluence Pharmaceuticals, Llc Sprinkle formulations of acamprosate

Also Published As

Publication number Publication date
EP3624788A1 (en) 2020-03-25
JP2023099100A (ja) 2023-07-11
US20200163895A1 (en) 2020-05-28
AU2021225172A1 (en) 2021-09-30
CA3062834A1 (en) 2018-11-22
ZA201908264B (en) 2022-03-30
AU2018269557B2 (en) 2021-06-03
JP7499539B2 (ja) 2024-06-14
IL270654B2 (en) 2024-07-01
IL270654B1 (en) 2024-03-01
WO2018213589A1 (en) 2018-11-22
AU2021225172B2 (en) 2023-04-06
KR20200005576A (ko) 2020-01-15
AU2018269557A1 (en) 2019-11-28
IL270654A (en) 2020-01-30
US12042566B2 (en) 2024-07-23
EP3624788A4 (en) 2021-03-03

Similar Documents

Publication Publication Date Title
RU2428176C2 (ru) Системы доставки лекарственного средства, содержащие слабоосновные лекарственные средства и органические кислоты
ES2739888T3 (es) Composiciones y comprimidos farmacéuticos con recubrimiento compresible y métodos de fabricación
AU2005307052B2 (en) Taste-masked multiparticulate pharmaceutical compositions comprising a drug-containing core particle and a solvent-coacervated membrane
JP6480420B2 (ja) コルヒチンの徐放性製剤およびその使用方法
US20100047343A1 (en) Multiparticulate formulation having tramadol in immediate and controlled release form
CN106390129A (zh) 含有高剂量和低剂量药物的组合的口腔崩解片组合物
US11883537B2 (en) Sustained release solid dosage forms for modulating the colonic microbiome
JP7026347B2 (ja) アカンプロサートのスプリンクル製剤
US8927010B2 (en) Compositions for treatment of attention deficit hyperactivity disorder
CN112789042A (zh) 用于治疗由毒蕈碱受体激活所缓解的障碍的组合物和方法
US9034902B2 (en) Methods for treatment of attention deficit hyperactivity disorder
JP7499539B2 (ja) ホモタウリンおよびその塩の製剤
US12472149B2 (en) Multilayered pharmaceutically active compound-releasing microparticles in a liquid dosage form
EP3331502B1 (en) Controlled release propiverine formulations
CN115667235A (zh) 用于治疗由毒蕈碱受体激活所缓解的障碍的组合物和方法
CA3062834C (en) Formulations of homotaurines and salts thereof
RU2325905C2 (ru) Содержащее 3-(3-диметиламино-1-этил-2-метилпропил)фенол лекарственное средство с замедленным высвобождением действующего вещества
US20080008772A1 (en) Narcotic biphasic release compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction
RU2744270C2 (ru) Прессованный фармацевтический препарат

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210513

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210513

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220822

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221227